Kriya Medical Technologies receives manufacturing license for its RT-qPCR kit [Video]

Krivida Trivus offers simultaneous detection of, RSV (Respiratory Syncytial Virus), Influenza Viruses and SARS-CoV-2 in a single swab sample

Kriya Medical Technologies has received its manufacturing license from the Central Drugs Standard Control Organization (CDSCO) for its product KRIVIDA Trivus Respi Panel RT-qPCR Kit. It that has the capability to simultaneously identify Respiratory Syncytial Virus (RSV), Influenza viruses and SARS-CoV-2 in patients presenting with respiratory tract infections.

KRIVIDA Trivus Respi Panel RT-qPCR kit has been validated by ICMR at National Institute of Virology, Pune, and the kit has shown 100 per cent specificity and 99.11 per cent sensitivity for the detection of all three viruses.

A key feature of this kit is its ability to detect RSV, a virus that primarily causes viral pneumonia in children under the age of 5 and contributes significantly to hospitalizations. Additionally, RSV is a common cause of lower respiratory tract diseases (LRTD) in older …